摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-Dimethylamino-2-cyan-2-<4-methyl-thiazolyl-(2)>-ethen

中文名称
——
中文别名
——
英文名称
1-Dimethylamino-2-cyan-2-<4-methyl-thiazolyl-(2)>-ethen
英文别名
3-dimethylamino-2-(4-methyl-thiazol-2-yl)-acrylonitrile;3-(Dimethylamino)-2-(4-methyl-1,3-thiazol-2-yl)prop-2-enenitrile;3-(dimethylamino)-2-(4-methyl-1,3-thiazol-2-yl)prop-2-enenitrile
1-Dimethylamino-2-cyan-2-<4-methyl-thiazolyl-(2)>-ethen化学式
CAS
——
化学式
C9H11N3S
mdl
——
分子量
193.272
InChiKey
RQLWQPCBYJIYRK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    68.2
  • 氢给体数:
    0
  • 氢受体数:
    4

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES POUR L'INHIBITION DE PASK
    申请人:BIOENERGENIX
    公开号:WO2014066795A1
    公开(公告)日:2014-05-01
    Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
    本文披露了新的杂环化合物和组合物,以及它们作为药物治疗疾病的应用。还提供了抑制PAS激酶(PASK)在人类或动物主体中活性的方法,用于治疗疾病,如糖尿病。
  • Organic compounds
    申请人:Bold Guido
    公开号:US20050222171A1
    公开(公告)日:2005-10-06
    The invention relates to the use of pyrazolo[1,5a]pyrimidin-7-yl amine compounds and salts thereof in the treatment of kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, novel pyrazolo[1,5a]pyrimidin-7-yl amine compounds, and a process for the preparation of the novel pyrazolo[1,5a]pyrimidin-7-yl amine compounds.
    该发明涉及在激酶依赖性疾病的治疗中使用吡唑并[1,5a]嘧啶-7-基胺化合物及其盐,并用于制备用于治疗该类疾病的药物制剂,新型吡唑并[1,5a]嘧啶-7-基胺化合物,以及制备新型吡唑并[1,5a]嘧啶-7-基胺化合物的方法。
  • Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders
    申请人:Sivasankaran Rajeev
    公开号:US20090069315A1
    公开(公告)日:2009-03-12
    The invention relates to methods of using the compounds of the invention, including pyrazolo[1,5a]pyrimidin-7-yl amine compounds and salts thereof, as well as pharmaceutical compositions comprising the same, in the treatment of Eph receptor-related (e.g., neurological) injuries and disorders. The invention also relates to modulating the activity of an Eph receptor in a cell, stimulating neural regeneration, and reversing neuronal degeneration, by administering a compound of the invention to a cell or subject in an effective amount.
    该发明涉及使用该发明的化合物的方法,包括吡唑并[1,5a]嘧啶-7-基胺化合物及其盐,以及包含相同的药物组合物,在治疗Eph受体相关(例如神经)损伤和疾病方面的用途。该发明还涉及通过向细胞或受体中有效量的给予该发明的化合物,来调节Eph受体的活性,刺激神经再生,并逆转神经细胞的退化。
  • [EN] PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES<br/>[FR] DERIVES DE PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DESTINES A ETRE UTILISES DANS LE TRAITEMENT DE MALADIES DEPENDANTES DE LA PROTEINE KINASE
    申请人:NOVARTIS AG
    公开号:WO2005070431A1
    公开(公告)日:2005-08-04
    The invention relates to the use of pyrazolo[1,5a]pyrimidin-7-yl amine compounds and salts thereof in the treatment of kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, novel pyrazolo[1,5a]pyrimidin-7-yl amine compounds, and a process for the preparation of the novel pyrazolo[1,5a]pyrimidin-7-yl amine compounds.
    该发明涉及使用吡唑并[1,5a]嘧啶-7-基胺化合物及其盐来治疗激酶依赖性疾病,并用于制备用于治疗该疾病的制药制剂,新的吡唑并[1,5a]嘧啶-7-基胺化合物,以及制备新的吡唑并[1,5a]嘧啶-7-基胺化合物的方法。
  • HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK
    申请人:MCCALL John
    公开号:US20150284395A1
    公开(公告)日:2015-10-08
    Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
    本文公开了新的杂环化合物和组合物以及它们作为药物治疗疾病的应用。还提供了抑制人类或动物主体中PAS激酶(PASK)活性的方法,以治疗糖尿病等疾病。
查看更多